Therefore, the clinical use of a specific inhibitor of gasdermin D for the activation of gasdermin E in tumor cells, and the blocking of gasdermin D, can prevent the occurrence of CRS while exerting CAR-T efficacy, thus improving the safety of treatment [51]. The gene discussed is GSDMD; the disease is congenital rubella syndrome.